Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cinacalcet hydrochloride, quantity: 66 mg (equivalent: cinacalcet, qty 60 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; crospovidone; hyprolose; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - cinacalcet may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis. cinacalcet should be used as adjunctive therapy. ,cinacalcet is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma. ,cinacalcet may be used to treat the biochemical manifestations of primary hyperparathyroidism in patients for whom parathyroidectomy is not a treatment option.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cinacalcet hydrochloride, quantity: 66 mg (equivalent: cinacalcet, qty 60 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; hyprolose; crospovidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - cinacalcet may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis. cinacalcet should be used as adjunctive therapy. ,cinacalcet is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma. ,cinacalcet may be used to treat the biochemical manifestations of primary hyperparathyroidism in patients for whom parathyroidectomy is not a treatment option.

Singapūra - angļu - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - estradiol valerate (in brown tablet); estradiol valerate (in white tablet); norgestrel (in brown tablet) - tablet, sugar coated - 2 mg - estradiol valerate (in brown tablet) 2 mg; estradiol valerate (in white tablet) 2 mg; norgestrel (in brown tablet) 0.5 mg

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - prazosin hydrochloride, quantity: 5.476 mg (equivalent: prazosin, qty 5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; magnesium stearate; sodium lauryl sulfate; maize starch - indications as at 31 april 2004: in patients with hypertension. minipress (prazosin hydrochloride) is indicated in the treatment of hypertension of varied aetiology and all grades of severity. it can be used as the initial and sole agent or it may be employed in a treatment programme in conjunction with other antihypertensive agents. renal blood flow and glomerular filtration rate are not impaired by long-term oral administration. minipress can be used with safety in hypertensive patients with impaired renal function. in patients with congestive heart failure. minipress is indicated in the treatment of severe refractory congestive heart failure. minipress may be added to the therapeutic regime in those patients who have become refractory to conventional therapy with cardiac glycosides and diuretics. in patients with raynaud's phenomenon and raynaud's disease. minipress is indicated in the treatment of raynaud's phenomenon and raynaud's disease. benign prostatic hyperplasia. minipress is indicated as an adjunc

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - prazosin hydrochloride, quantity: 2.19 mg (equivalent: prazosin, qty 2 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; magnesium stearate; sodium lauryl sulfate; maize starch - indications as at 30 april 2004: in patients with hypertension. minipress (prazosin hydrochloride) is indicated in the treatment of hypertension of varied aetiology and all grades of severity. it can be used as the initial and sole agent or it may be employed in a treatment programme in conjunction with other antihypertensive agents. renal blood flow and glomerular filtration rate are not impaired by long-term oral administration. minipress can be used with safety in hypertensive patients with impaired renal function. in patients with congestive heart failure. minipress is indicated in the treatment of severe refractory congestive heart failure. minipress may be added to the therapeutic regime in those patients who have become refractory to conventional therapy with cardiac glycosides and diuretics. in patients with raynaud's phenomenon and raynaud's disease. minipress is indicated in the treatment of raynaud's phenomenon and raynaud's disease. benign prostatic hyperplasia. minipress is indicated as an adjunc

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - prazosin hydrochloride, quantity: 1.095 mg (equivalent: prazosin, qty 1 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; magnesium stearate; sodium lauryl sulfate; sunset yellow fcf; maize starch - indications as at 30 april 2004: in patients with hypertension. minipress (prazosin hydrochloride) is indicated in the treatment of hypertension of varied aetiology and all grades of severity. it can be used as the initial and sole agent or it may be employed in a treatment programme in conjunction with other antihypertensive agents. renal blood flow and glomerular filtration rate are not impaired by long-term oral administration. minipress can be used with safety in hypertensive patients with impaired renal function. in patients with congestive heart failure. minipress is indicated in the treatment of severe refractory congestive heart failure. minipress may be added to the therapeutic regime in those patients who have become refractory to conventional therapy with cardiac glycosides and diuretics. in patients with raynaud's phenomenon and raynaud's disease. minipress is indicated in the treatment of raynaud's phenomenon and raynaud's disease. benign prostatic hyperplasia. minipress is indicated as an adjunc

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - finasteride, quantity: 5 mg - tablet, film coated - excipient ingredients: magnesium stearate; lauroyl macrogolglycerides; lactose monohydrate; pregelatinised maize starch; microcrystalline cellulose; sodium starch glycollate type a; titanium dioxide; hypromellose; macrogol 6000; indigo carmine aluminium lake - finasteride gh 5 5 mg is indicated for the treatment of patients with symptomatic benign prostatic hyperplasia (bph) with an enlarged prostate.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - prazosin hydrochloride, quantity: 5.5 mg (equivalent: prazosin, qty 5 mg) - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; polysorbate 80; croscarmellose sodium; magnesium stearate - in patients with hypertension: prazosin is indicated in the treatment of hypertension of varied aetiology and all grades of severity. it can be used as the initial and sole agent or it may be employed in a general treatment programme in conjunction with other antihypertensive agents. renal blood flow and glomerular filtration rate are not impaired by long term oral administration. prazosin can be used with safety in hypertensive patients with impaired renal function. in patients with congestive heart failure: prazosin is indicated in the treatment of severe refractory congestive heart failure. prazosin may be added to the therapeutic regimen in those patients who have become refractory to conventional therapy with cardiac glycosides and diuretics. in patients with raynaud's phenomenon and raynaud's disease: prazosin is indicated in the treatment of raynaud's phenomenon and raynaud's disease. benign prostatic hyperplasia: prazosin is indicated as an adjunct in the symptomatic treatment of urinary obstruction caused by benign prostatic hyperplasia in patients awaiting prostatic surgery.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - prazosin hydrochloride, quantity: 2.2 mg (equivalent: prazosin, qty 2 mg) - tablet, uncoated - excipient ingredients: croscarmellose sodium; lactose monohydrate; polysorbate 80; magnesium stearate; microcrystalline cellulose - in patients with hypertension: prazosin is indicated in the treatment of hypertension of varied aetiology and all grades of severity. it can be used as the initial and sole agent or it may be employed in a general treatment programme in conjunction with other antihypertensive agents. renal blood flow and glomerular filtration rate are not impaired by long term oral administration. prazosin can be used with safety in hypertensive patients with impaired renal function. in patients with congestive heart failure: prazosin is indicated in the treatment of severe refractory congestive heart failure. prazosin may be added to the therapeutic regimen in those patients who have become refractory to conventional therapy with cardiac glycosides and diuretics. in patients with raynaud's phenomenon and raynaud's disease: prazosin is indicated in the treatment of raynaud's phenomenon and raynaud's disease. benign prostatic hyperplasia: prazosin is indicated as an adjunct in the symptomatic treatment of urinary obstruction caused by benign prostatic hyperplasia in patients awaiting prostatic surgery.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - prazosin hydrochloride, quantity: 1.1 mg (equivalent: prazosin, qty 1 mg) - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; polysorbate 80 - in patients with hypertension: prazosin is indicated in the treatment of hypertension of varied aetiology and all grades of severity. it can be used as the initial and sole agent or it may be employed in a general treatment programme in conjunction with other antihypertensive agents. renal blood flow and glomerular filtration rate are not impaired by long term oral administration. prazosin can be used with safety in hypertensive patients with impaired renal function. in patients with congestive heart failure: prazosin is indicated in the treatment of severe refractory congestive heart failure. prazosin may be added to the therapeutic regimen in those patients who have become refractory to conventional therapy with cardiac glycosides and diuretics. in patients with raynaud's phenomenon and raynaud's disease: prazosin is indicated in the treatment of raynaud's phenomenon and raynaud's disease. benign prostatic hyperplasia: prazosin is indicated as an adjunct in the symptomatic treatment of urinary obstruction caused by benign prostatic hyperplasia in patients awaiting prostatic surgery.